Literature DB >> 24284783

β-Elemene, a compound derived from Rhizoma zedoariae, reverses multidrug resistance mediated by the ABCB1 transporter.

Hui-Qin Guo1, Guan-Nan Zhang2, Yi-Jun Wang2, Yun-Kai Zhang2, Kamlesh Sodani2, Tanaji T Talele2, Charles R Ashby2, Zhe-Sheng Chen2.   

Abstract

In the present in vitro study, we examined the effect of the compound β-elemene on the response of KB-C2 cells overexpressing the ABCB1 transporter to specific antineoplastic compounds. The MTT assay was used to determine the effects of β-elemene in combination with other anticancer drugs on ABCB1-overexpressing cancer cell lines. Furthermore, we used [3H]-paclitaxel accumulation, efflux assay, immunofluorescence experiments, western blot assays and docking analysis to ascertain the mechanism of action of β-elemene. The incubation of KB-C2 cells overexpressing ABCB1 transporter with β-elemene (100 µM) significantly augmented the antineoplastic efficacy of colchicine, vinblastine and paclitaxel when compared to KB-C2 cells incubated with these drugs alone. In HEK293 cells overexpressing the ABCB1 transporter, β-elemene significantly increased the cytotoxicity of paclitaxel. In addition, 100 µM of β-elemene significantly increased the accumulation of [3H]-paclitaxel and this was due to a decrease in [3H]-paclitaxel efflux when compared to controls. The incubation of KB-C2 cells with β-elemene (100 µM) for 72 h did not significantly alter the expression of ABCB1 protein levels. Immunofluorescence experiments indicated that β-elemene did not significantly alter the subcellular localization of the ABCB1 transporter. Docking analysis indicated that β-elemene binds to the drug-binding site of ABCB1 transporter. Finally, β-elemene at 100 µM partially (~50%) increased the sensitivity of the BCRP-overexpressing cell line, NCI-H460/MX20, to mitoxantrone, but β-elemene did not significantly alter the resistance of MRP1-transfected HEK293/MRP1 cells to vincristine. Overall, our in vitro findings indicated that β-elemene potentiates the cytotoxic effects of various antineoplastic drugs in cell lines overexpressing the ABCB1 transporter and that this is due to the inhibition of the efflux component of the ABCB1 transporter.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24284783     DOI: 10.3892/or.2013.2870

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  21 in total

1.  Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib.

Authors:  Guan-Nan Zhang; Yun-Kai Zhang; Yi-Jun Wang; Anna Maria Barbuti; Xi-Jun Zhu; Xin-Yue Yu; Ai-Wen Wen; John N D Wurpel; Zhe-Sheng Chen
Journal:  Pharmacol Res       Date:  2017-01-25       Impact factor: 7.658

2.  Preliminary evaluation of the potential role of β-elemene in reversing erlotinib-resistant human NSCLC A549/ER cells.

Authors:  Lan Lin; Lianbin Li; Xiangqi Chen; Bangwei Zeng; Tingyan Lin
Journal:  Oncol Lett       Date:  2018-06-18       Impact factor: 2.967

3.  Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study.

Authors:  Yi-Jun Wang; Yun-Kai Zhang; Guan-Nan Zhang; Sweilem B Al Rihani; Meng-Ning Wei; Pranav Gupta; Xiao-Yu Zhang; Suneet Shukla; Suresh V Ambudkar; Amal Kaddoumi; Zhi Shi; Zhe-Sheng Chen
Journal:  Cancer Lett       Date:  2017-03-14       Impact factor: 8.679

4.  Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.

Authors:  Yi-Jun Wang; Rishil J Kathawala; Yun-Kai Zhang; Atish Patel; Priyank Kumar; Suneet Shukla; King Leung Fung; Suresh V Ambudkar; Tanaji T Talele; Zhe-Sheng Chen
Journal:  Biochem Pharmacol       Date:  2014-06-14       Impact factor: 5.858

5.  Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.

Authors:  Hui Zhang; Rishil J Kathawala; Yi-Jun Wang; Yun-Kai Zhang; Atish Patel; Suneet Shukla; Robert W Robey; Tanaji T Talele; Charles R Ashby; Suresh V Ambudkar; Susan E Bates; Li-Wu Fu; Zhe-Sheng Chen
Journal:  Int J Biochem Cell Biol       Date:  2014-04-12       Impact factor: 5.085

6.  β-elemene reverses the drug resistance of A549/DDP lung cancer cells by activating intracellular redox system, decreasing mitochondrial membrane potential and P-glycoprotein expression, and inducing apoptosis.

Authors:  Chengcai Yao; Jie Jiang; Yuanrong Tu; Shefang Ye; Haoxin Du; Yi Zhang
Journal:  Thorac Cancer       Date:  2014-07-03       Impact factor: 3.500

7.  Demethylation effects of elemene on the GSTP1 gene in HCC cell line QGY7703.

Authors:  Baoqiang Wu; Yong Jiang; Feng Zhu; Donglin Sun; Hongjun Huang
Journal:  Oncol Lett       Date:  2016-02-18       Impact factor: 2.967

Review 8.  The reversal of antineoplastic drug resistance in cancer cells by β-elemene.

Authors:  Guan-Nan Zhang; Charles R Ashby; Yun-Kai Zhang; Zhe-Sheng Chen; Huiqin Guo
Journal:  Chin J Cancer       Date:  2015-09-14

Review 9.  Overcome Cancer Cell Drug Resistance Using Natural Products.

Authors:  Pu Wang; Hua Li Yang; Ying Juan Yang; Lan Wang; Shao Chin Lee
Journal:  Evid Based Complement Alternat Med       Date:  2015-09-01       Impact factor: 2.629

10.  β-elemene alleviates airway stenosis via the ILK/Akt pathway modulated by MIR143HG sponging miR-1275.

Authors:  Guoying Zhang; Cheng Xue; Yiming Zeng
Journal:  Cell Mol Biol Lett       Date:  2021-06-12       Impact factor: 5.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.